Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial by Estela Pineda, A Salud, E Vila-Navarro, MJ Safont, Beatriz Llorente, J Aparicio, R Vera, P Escudero, E Casado, C Bosch, U Bohn, R Pérez-Carrión, A Carmona, JR Ayuso, T Ripollés, R Bouzas, M Gironella, X García-Albéniz, J Feliu, J Maurel

Get full text